<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518466</url>
  </required_header>
  <id_info>
    <org_study_id>OB-102 / AA42851</org_study_id>
    <nct_id>NCT00518466</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults</brief_title>
  <official_title>A Phase Ib, Open Label, Parallel-Design Single- and Multiple-Dose Study Comparing Modified Release Topiramate Formulations to Immediate Release Formulations of Topiramate Dosed in Combination With Immediate Release Phentermine in Obese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to describe the single- and multiple-dose
      pharmacokinetic profiles of two novel formulations of topiramate and commercially available
      immediate release topiramate, all dosed with immediate release phentermine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.
One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.
One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.
One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.
One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2.
Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.
Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.
One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.
Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2.
Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.
Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1.
One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2.
Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2.
Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2.
Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topiramate</intervention_name>
    <description>25 mg modified-release capsules</description>
    <arm_group_label>treatment 1</arm_group_label>
    <arm_group_label>treatment 2</arm_group_label>
    <arm_group_label>treatment 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phentermine</intervention_name>
    <description>7.5 mg immediate-release capsules</description>
    <arm_group_label>treatment 1</arm_group_label>
    <arm_group_label>treatment 2</arm_group_label>
    <arm_group_label>treatment 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topiramate</intervention_name>
    <description>100 and 25 mg immediate-release tablets</description>
    <arm_group_label>treatment 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phentermine</intervention_name>
    <description>37.5 and 7.5 mg immediate-release tablets</description>
    <arm_group_label>treatment 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese adults

          -  Body mass index between 30.0 and 42.0 kg/m2 (inclusive)

          -  Medically healthy with no clinically significant results of screening exams

        Exclusion Criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric
             disease

          -  History of glaucoma or increased intraocular pressure

          -  History of kidney stones

          -  Cholelithiasis or cholecystitis within 6 months

          -  Cardiovascular event within 6 months

          -  Obesity of known genetic or endocrine origin

          -  Recent weight instability

          -  Use of Very Low Calorie diet or participation in organized weight loss program within
             3 months

          -  Systolic blood pressure &gt; 150 or diastolic &gt; 95 mm Hg

          -  Positive urine drug or alcohol screen

          -  Positive serology for HIV, HBV, or HCV

          -  History of alcoholism or drug abuse

          -  History of significant psychiatric disease, current depression of moderate or greater
             severity, any history of suicidal ideation

          -  Hypersensitivity to study drug or related compounds

          -  Use of prescription or OTC medication other than hormonal contraceptive within 14 days
             prior to first dosing with study drug

          -  Blood donation or significant blood loss within 56 days or plasma donation within 7
             days prior to first dosing with study drug

          -  Women who are pregnant or lactating

          -  Hemoglobin &lt; 12 g/dL

          -  Use of tobacco or nicotine-containing products within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wesley W Day, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VIVUS, Inc.</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2007</study_first_submitted>
  <study_first_submitted_qc>August 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wesley Day, VP Clinical</name_title>
    <organization>Vivus, Inc.</organization>
  </responsible_party>
  <keyword>Obesity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

